Mechanism of Action of Warfarin
Warfarin produces its anticoagulant effect by inhibiting vitamin K epoxide reductase (VKORC1), which blocks the cyclic regeneration of vitamin K, thereby preventing the hepatic synthesis of functional vitamin K-dependent clotting factors II, VII, IX, and X, as well as the anticoagulant proteins C and S. 1, 2
The Vitamin K Cycle and Warfarin's Interruption
Warfarin interferes with a critical enzymatic cycle in the liver:
- Vitamin K is essential for the post-ribosomal carboxylation of glutamate residues to γ-carboxyglutamates (Gla) on vitamin K-dependent proteins 1
- This carboxylation step is required for these clotting factors to bind to phospholipid surfaces and function properly in the coagulation cascade 1
- The carboxylation process requires the reduced form of vitamin K (vitamin KH₂) 1
Warfarin specifically blocks vitamin K epoxide reductase, the enzyme that converts vitamin K epoxide back to vitamin K and then to its reduced form (KH₂). By inhibiting this enzyme, warfarin depletes the substrate needed for carboxylation, resulting in the hepatic production of partially decarboxylated, biologically inactive clotting factors 1, 2.
Clinical Implications of the Mechanism
The mechanism explains several important clinical features:
Delayed onset of action: The anticoagulant effect generally occurs within 24 hours, but peak effect may be delayed 72-96 hours because warfarin doesn't affect already-circulated clotting factors—it only prevents synthesis of new functional factors 2
Sequential factor depression: Factors are depleted based on their half-lives—Factor VII first (4-6 hours), then Factor IX (24 hours), Factor X (48-72 hours), and finally Factor II (60 hours) 2
Vitamin K reversal: Low doses of vitamin K₁ (phytonadione) can overcome warfarin's effect because vitamin K₁ bypasses the blocked vitamin K epoxide reductase step 1. However, large doses (≥5 mg) can cause warfarin resistance for up to a week as vitamin K₁ accumulates in the liver 1
Stereochemistry and Potency
Warfarin is a racemic mixture of R- and S-enantiomers. The S-enantiomer is approximately 5 times more potent than the R-enantiomer as a vitamin K antagonist and is primarily metabolized by CYP2C9 3, 2. This stereoselectivity is clinically relevant because drugs that inhibit CYP2C9 metabolism of S-warfarin can significantly potentiate anticoagulation 3.
Additional Effects
Beyond coagulation factors, warfarin also inhibits carboxylation of: